Utility of Growth Differentiation Factor-15, A Marker of Oxidative Stress and Inflammation, in Chronic Heart Failure: Insights From the HF-ACTION Study

JACC: Heart Failure

Volumn 5, Issue 10, 2017, Pages 724-734

  Sharma, Abhinav ^a   Stevens, Susanna R ^a   Lucas, Joseph ^a   Fiuzat, Mona ^a   Adams, Kirkwood F ^b   Whellan, David J ^c   Donahue, Mark P ^d   Kitzman, Dalane W ^e   Piña, Ileana L ^f   Zannad, Faiez ^g   Kraus, William E ^d   O'Connor, Christopher M ^h   Felker, G Michael ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e WAKE FOREST SCHOOL OF MEDICINE   (United States)

^f ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^g UNIVERSITÉ DE LORRAINE   (France)

^h INOVA HEART AND VASCULAR INSTITUTE   (United States)

Author keywords

B type natriuretic peptide; BNP; heart failure; N terminal pro B type natriuretic peptide

Indexed keywords

ALDOSTERONE ANTAGONIST; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GROWTH DIFFERENTIATION FACTOR 15; LOOP DIURETIC AGENT; TROPONIN T; BRAIN NATRIURETIC PEPTIDE; GDF15 PROTEIN, HUMAN; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ADULT; AGE; AGED; ALL CAUSE MORTALITY; ARTICLE; ARTIFICIAL HEART PACEMAKER; CARDIOPULMONARY EXERCISE TEST; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; EXERCISE; FEMALE; FUNCTIONAL STATUS; HEART FAILURE WITH REDUCED EJECTION FRACTION; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; OXYGEN CONSUMPTION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; TREATMENT OUTCOME; BLOOD; CHRONIC DISEASE; HEART FAILURE; HEART STROKE VOLUME; IMMUNOLOGY; KINESIOTHERAPY; MIDDLE AGED; PATHOPHYSIOLOGY; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEVERITY OF ILLNESS INDEX;

ADULT; AGED; CHRONIC DISEASE; EXERCISE THERAPY; FEMALE; GROWTH DIFFERENTIATION FACTOR 15; HEART FAILURE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; OXIDATIVE STRESS; PEPTIDE FRAGMENTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX; STROKE VOLUME;

EID: 85029951233     PISSN: 22131779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchf.2017.07.013     Document Type: Article

References (29)

1. Maisel, A.S., Krishnaswamy, P., Nowak, R.M., et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 347 (2002), 161–167.
2. Writing Group Members, Mozaffarian, D., Benjamin, E.J., et al. Heart disease and stroke statistics-2016 update: a report from the American Heart Association. Circulation 133 (2016), e38–e60.
3. Curtis, L.H., Whellan, D.J., Hammill, B.G., et al. Incidence and prevalence of heart failure in elderly persons, 1994-2003. Arch Intern Med 168 (2008), 418–424.
4. Braunwald, E., The war against heart failure: the Lancet lecture. Lancet 385 (2015), 812–824.
5. Yancy, C.W., Jessup, M., Bozkurt, B., et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 62 (2013), e147–e239.
6. Thygesen, K., Mair, J., Mueller, C., et al. Recommendations for the use of natriuretic peptides in acute cardiac care: a position statement from the Study Group on Biomarkers in Cardiology of the ESC Working Group on Acute Cardiac Care. Eur Heart J 33 (2012), 2001–2006.
7. Kempf, T., Zarbock, A., Widera, C., et al. GDF-15 is an inhibitor of leukocyte integrin activation required for survival after myocardial infarction in mice. Nat Med 17 (2011), 581–588.
8. Kempf, T., Eden, M., Strelau, J., et al. The transforming growth factor-beta superfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfusion injury. Circ Res 98 (2006), 351–360.
9. Xu, J., Kimball, T.R., Lorenz, J.N., et al. GDF-15/MIC-1 functions as a protective and antihypertrophic factor released from the myocardium in association with SMAD protein activation. Circ Res 98 (2006), 342–350.
10. Ponikowski, P., Voors, A.A., Anker, S.D., et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 37 (2016), 2129–2200.
11. Wallentin, L., Hijazi, Z., Andersson, U., et al. Growth differentiation factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Circulation 130 (2014), 1847–1858.
12. Wollert, K.C., Kempf, T., Lagerqvist, B., Lindahl, B., Growth differentiation factor 15 for risk stratification and selection of an invasive treatment strategy in non–st-elevation acute coronary syndrome. Circulation 116 (2007), 1540–1548.
13. Daniels, L.B., Clopton, P., Laughlin, G.A., Maisel, A.S., Barrett-Connor, E., Growth-differentiation factor-15 is a robust, independent predictor of 11-year mortality risk in community-dwelling older adults: the Rancho Bernardo study. Circulation 123 (2011), 2101–2110.
14. Eggers, K.M., Kempf, T., Lagerqvist, B., et al. Growth-differentiation factor-15 for long-term risk prediction in patients stabilized after an episode of nonST-segment-elevation acute coronary syndrome. Circ Cardiovasc Genet 3 (2010), 88–96.
15. Dallmeier, D., Brenner, H., Mons, U., Rottbauer, W., Koenig, W., Rothenbacher, D., Growth differentiation factor 15, its 12-month relative change, and risk of cardiovascular events and total mortality in patients with stable coronary heart disease: 10-year follow-up of the KAROLA Study. Clin Chem 62 (2016), 982–992.
16. Anand, I.S., Kempf, T., Rector, T.S., et al. Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the valsartan heart failure trial. Circulation 122 (2010), 1387–1395.
17. Whellan, D.J., O'Connor, C.M., Lee, K.L., et al. Heart Failure and A Controlled Trial Investigating Outcomes of Exercise TraiNing (HF-ACTION): design and rationale. Am Heart J 153 (2007), 201–211.
18. O'Connor, C.M., Whellan, D.J., Lee, K.L., et al. Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA 301 (2009), 1439–1450.
19. Wollert, K.C., Kempf, T., Giannitsis, E., et al. An automated assay for growth differentiation factor 15. J App Lab Med 1 (2017), 510–521.
20. O'Connor, C.M., Whellan, D.J., Wojdyla, D., et al. Factors related to morbidity and mortality in patients with chronic heart failure with systolic dysfunction: the HF-ACTION predictive risk score model. Circ Heart Fail 5 (2012), 63–71.
21. Januzzi, J.L., Camargo, C.A., Anwaruddin, S., et al. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol 95 (2005), 948–954.
22. Kim, H.-N., Januzzi, J.L., Natriuretic peptide testing in heart failure. Circulation 123 (2011), 2015–2019.
23. Kempf, T., Horn-Wichmann, R., Brabant, G., et al. Circulating concentrations of growth-differentiation factor 15 in apparently healthy elderly individuals and patients with chronic heart failure as assessed by a new immunoradiometric sandwich assay. Clin Chem 53 (2006), 284–291.
24. Kempf, T., Haehling von, S., Peter, T., et al. Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure. J Am Coll Cardiol 50 (2007), 1054–1060.
25. Felker, G.M., Fiuzat, M., Shaw, L.K., et al. Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study. Circ Heart Fail 5 (2012), 72–78.
26. Felker, G.M., Fiuzat, M., Thompson, V., et al. Soluble ST-2 in ambulatory patients with heart failure: association with functional capacity and long-term outcomes. Circ Heart Fail 6 (2013), 1172–1179.
27. Balady, G.J., Arena, R., Sietsema, K., et al. Clinician's guide to cardiopulmonary exercise testing in adults: a scientific statement from the American Heart Association. Circulation 122 (2010), 191–225.
28. Chan, M.M.Y., Santhanakrishnan, R., Chong, J.P.C., et al. Growth differentiation factor 15 in heart failure with preserved vs. reduced ejection fraction. Eur J Heart Fail 18 (2015), 81–88.
29. Fonarow, G.C., Albert, N.M., Curtis, A.B., et al. Improving evidence-based care for heart failure in outpatient cardiology practices: primary results of the registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF). Circulation 122 (2010), 585–596.